Brought to you by 
FibroGen licenses anemia candidate to Yamanouchi
24 Oct 2014
Executive Summary
Japanese drug company Yamanouchi Pharmaceutical has licensed exclusive rights in Japan to further develop and sell FibroGen's (fibrotic disease therapies) FG-2216, a small-molecule candidate in clinical trials for anemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com